Earnings summaries and quarterly performance for MYRIAD GENETICS.
Executive leadership at MYRIAD GENETICS.
Sam S. Raha
Detailed
President and Chief Executive Officer
CEO
BR
Ben R. Wheeler
Detailed
Chief Financial Officer
DM
Dale Muzzey
Detailed
Chief Scientific Officer
JF
Jennifer Fox
Detailed
Chief Legal Officer
KR
Kevin R. Haas
Detailed
Chief Technology Officer
MA
Margaret Ancona
Detailed
Senior Vice President, Chief of Staff
MV
Mark Verratti
Detailed
Chief Operating Officer
SS
Shereen Solaiman
Detailed
Chief People Officer
Board of directors at MYRIAD GENETICS.
CF
Colleen F. Reitan
Detailed
Director
DM
Daniel M. Skovronsky, M.D., Ph.D.
Detailed
Director
HD
Heiner Dreismann, Ph.D.
Detailed
Director
LN
Lee N. Newcomer, M.D.
Detailed
Director
MS
Mark S. Davis
Detailed
Director
PM
Paul M. Bisaro
Detailed
Director
RK
Rashmi Kumar
Detailed
Director
SL
S. Louise Phanstiel
Detailed
Chair of the Board
Research analysts who have asked questions during MYRIAD GENETICS earnings calls.
PS
Puneet Souda
Leerink Partners
6 questions for MYGN
Also covers: A, ABCL, BRKR +20 more
Tycho Peterson
Jefferies
6 questions for MYGN
Also covers: A, AVTR, BIO +22 more
MC
Mason Carrico
Stephens Inc.
4 questions for MYGN
Also covers: AKYA, CDNA, CSTL +13 more
SJ
Sung Ji Nam
Scotiabank
4 questions for MYGN
Also covers: ADPT, BDSX, BNGO +9 more
Andrew Cooper
Raymond James
3 questions for MYGN
Also covers: AZTA, CDNA, CTKB +12 more
Bill Bonello
Craig-Hallum Capital Group LLC
3 questions for MYGN
Also covers: ADPT, BDSX, CDNA +8 more
DB
Dan Brennan
UBS
3 questions for MYGN
Also covers: A, ADPT, AVTR +17 more
Doug Schenkel
Wolfe Research LLC
3 questions for MYGN
Also covers: A, AVTR, BRKR +19 more
LL
Lu Li
Scotiabank
3 questions for MYGN
Also covers: FLGT, HOLX, QDEL +2 more
Brandon Couillard
Wells Fargo & Company
2 questions for MYGN
Also covers: A, AVTR, BIO +10 more
David Westenberg
Piper Sandler
2 questions for MYGN
Also covers: ADPT, AKYA, BLLN +14 more
Douglas Schenkel
Wolfe Research, LLC
2 questions for MYGN
Also covers: A, AVTR, BRKR +21 more
Michael Ryskin
Bank of America Merrill Lynch
2 questions for MYGN
Also covers: A, ALGN, AVTR +29 more
Subbu Nambi
Guggenheim Securities
2 questions for MYGN
Also covers: ADPT, BOLD, BRKR +21 more
TS
Tejas Savant
Morgan Stanley
2 questions for MYGN
Also covers: ADPT, AKYA, AVTR +19 more
Ben...
Stephens Inc.
1 question for MYGN
Also covers: ABBNY, CPRX, HBAN +1 more
JL
Jason Lai
Citigroup
1 question for MYGN
Also covers: DNA, NAUT, SEER
KB
Kyle Boucher
TD Cowen
1 question for MYGN
Also covers: LAB, SEER, SOPH +2 more
Madison Pasterchick
Morgan Stanley
1 question for MYGN
Also covers: PSNL
MS
Matt Sik
Goldman Sachs
1 question for MYGN
PK
Prashant Kota
Goldman Sachs
1 question for MYGN
Also covers: CDNA, NEO
RV
Rachel Vatnsdal Olson
JPMorgan
1 question for MYGN
Also covers: A, ADPT, AKYA +14 more
RL
Ricki Levitus
Guggenheim Securities, LLC
1 question for MYGN
Also covers: CSTL, NTRA
SN
Subhalaxmi Nambi
Guggenheim Securities
1 question for MYGN
Also covers: AKYA, BRKR, CSTL +15 more
T
Thomas...
Guggenheim Securities, LLC
1 question for MYGN
Also covers: ARDX, FBK, NEO +2 more
William Bonello
Craig-Hallum Capital Group
1 question for MYGN
Also covers: BDSX, CDNA, CERS +6 more
Recent press releases and 8-K filings for MYGN.
Myriad Genetics Reports Q4 2025 Results and Provides 2026 Guidance
MYGN
Earnings
Guidance Update
Product Launch
- Myriad Genetics reported Q4 2025 revenue of $210 million and full-year 2025 revenue of $824.5 million, with adjusted EPS of $0.04 and adjusted EBITDA of $14.3 million for Q4.
- The company issued full-year 2026 revenue guidance of $860 million to $880 million, with Q1 2026 revenue expected between $200 million and $203 million.
- Key product launches include the alpha launch of Precise MRD for breast cancer in Q1 2026, an AI-enhanced Prolaris prostate cancer test in Q2 2026, and the FirstGene multiple prenatal screen tests in H2 2026.
- MyRisk test volume grew 14% in the affected market and 11% in the unaffected market, and GeneSight volume increased 9% year-over-year in Q4 2025; however, prenatal volume declined in Q4 2025 and is expected to decline in Q1 2026 before recovering.
4 days ago
Myriad Genetics Reports Q4 2025 Results and Provides 2026 Guidance
MYGN
Earnings
Guidance Update
Product Launch
- Myriad Genetics reported Q4 2025 revenue of $209.8 million and adjusted EPS of $0.04.
- The company reaffirmed its full-year 2026 financial guidance, projecting revenue between $860 million and $880 million, adjusted gross margin of 68%-69%, and adjusted EBITDA of $37 million-$49 million.
- Several new products are slated for launch in 2026, including the AI-enhanced Prolaris prostate cancer test in Q2, the FirstGene multiple prenatal screen test in the second half, and the start of commercial testing for Precise MRD for breast cancer for select customers in Q1, though no revenue contribution from MRD is expected in 2026.
- Myriad plans to invest over $35 million over the next few years to enhance commercial capabilities and will reorganize its financial reporting into cancer care continuum, prenatal health, and mental health segments starting Q1 2026.
4 days ago
Myriad Genetics Announces Q4 and Full Year 2025 Financial Results and 2026 Guidance
MYGN
Earnings
Guidance Update
Revenue Acceleration/Inflection
- Myriad Genetics reported Q4 2025 total revenue of $209.8 million and Adjusted EPS of $0.04.
- For the full year 2025, the company achieved total revenue of $824.5 million and Adjusted EBITDA of $38.9 million.
- The documents provide conflicting information regarding the Adjusted EPS for the full year 2025, with values of $0.15 , $0.51 , and $0.06.
- The company provided FY 2026 guidance, projecting total revenue between $850 million and $870 million and Adjusted EPS between $0.60 and $0.70.
4 days ago
Myriad Genetics Reports Q4 and Full Year 2025 Results, Provides 2026 Guidance, and Details Product Pipeline
MYGN
Earnings
Guidance Update
Product Launch
- Myriad Genetics reported Q4 2025 revenue of $209.8 million and adjusted EPS of $0.04, with underlying revenue growth of 4% year-over-year (excluding UnitedHealthcare's GeneSight impact). Full year 2025 revenue reached $824.5 million.
- The company reaffirmed its full year 2026 financial guidance, expecting revenue between $860 million and $880 million, adjusted gross margin of 68% to 69%, and adjusted EBITDA of $37 million to $49 million.
- Key products demonstrated strong Q4 2025 year-over-year volume growth, including MyRisk in oncology (14%), MyRisk for unaffected (11%), Prolaris (12%), and GeneSight (9%). Prenatal volume declined in Q4 2025 but is anticipated to recover in 2026.
- Myriad Genetics is set to launch several new products in 2026, including the alpha phase of Precise MRD for breast cancer next week, an AI-enhanced Prolaris test in Q2, and FirstGene multiple prenatal screen tests in the second half of the year.
- The company plans to invest over $35 million over the next few years to boost organizational efficiency and commercial capabilities, including adding sales and medical headcount, and will restructure its reporting into cancer care continuum, prenatal health, and mental health segments.
4 days ago
Myriad Genetics Reports Q4 and Full-Year 2025 Financial Results, Reaffirms 2026 Guidance
MYGN
Earnings
Guidance Update
Product Launch
- Myriad Genetics reported Q4 2025 revenue of $209.8 million and full-year 2025 revenue of $824.5 million.
- The company recorded a Q4 2025 GAAP net loss of $7.9 million, or $0.08 per share, with adjusted EPS at $0.04 per share and adjusted EBITDA at $14.3 million.
- Total test volumes for Q4 2025 increased 2% year-over-year to 382,000.
- Myriad Genetics reiterated its full-year 2026 financial guidance, expecting revenue between $860 million and $880 million and adjusted EBITDA between $37 million and $49 million.
- The company plans three significant new test launches in 2026, including Precise MRD (alpha launch in March), an AI-enabled Prolaris prostate cancer test (Q2), and FirstGene (H2).
4 days ago
Myriad Genetics Reports Q4 and Full-Year 2025 Financial Results and Reaffirms 2026 Guidance
MYGN
Earnings
Guidance Update
Product Launch
- Myriad Genetics reported fourth quarter 2025 revenue of $209.8 million and full year 2025 revenue of $824.5 million.
- For Q4 2025, the company posted a GAAP net loss of $7.9 million ($0.08 per share) and adjusted EPS of $0.04 per share, with a gross margin of 70.0%.
- The company reaffirmed its full-year 2026 financial guidance, projecting revenue between $860 million and $880 million, an adjusted gross margin of 68% to 69%, and adjusted EBITDA of $37 million to $49 million.
- Key test volume growth in Q4 2025 year-over-year included Prolaris prostate cancer test at 12%, Hereditary cancer testing at 9%, and GeneSight at 9%.
- Myriad Genetics plans three significant new test launches in 2026: Precise MRD, an AI-enabled Prolaris prostate cancer test, and the multiple prenatal screen test, FirstGene.
4 days ago
Myriad Genetics Announces Precise MRD Commercialization Timeline and Study Data
MYGN
Product Launch
New Projects/Investments
- Myriad Genetics announced a commercialization roadmap for its Precise MRD™ assay, a tumor-informed circulating tumor DNA (ctDNA) test designed for ultrasensitive detection.
- The company plans to launch Precise MRD with select clinicians in March 2026 for breast cancer, followed by colorectal and renal cancers later in 2026, with potential expansion into ovarian and endometrial cancers in 2027 and beyond.
- Data from the MONITOR-Breast study showed 93% baseline sensitivity for Precise MRD in breast cancer, with early ctDNA clearance significantly associated with pathological complete response.
- Interim results from the MONSTAR-SCREEN-3 study for colorectal cancer demonstrated 100% baseline ctDNA detection and 100% sensitivity at one-month post-surgery in predicting recurrence.
Jan 27, 2026, 1:50 PM
Myriad Genetics Updates on 2025 Results and 2026 Guidance at J.P. Morgan Healthcare Conference
MYGN
Guidance Update
Product Launch
New Projects/Investments
- Myriad Genetics reported preliminary Q4 2025 revenue between $207 million and $209 million and full-year 2025 revenue between $822 million and $824 million, with overall volume growth of 1% for the year.
- For 2026, the company provided guidance of $860 million to $880 million in revenue, representing 6% growth at the midpoint, with gross margins of 68%-69% and adjusted EBITDA between $37 million and $49 million.
- The company plans to achieve high-single-digit to low-double-digit revenue growth over the next five years, starting in 2025, by focusing on the cancer care continuum and expanding its product portfolio.
- Key product developments for 2026 include the launch of an AI-enabled Prolaris test in the first half, initial testing and MolDX submissions for the Precise MRD test, and the full commercial launch of FirstGene in the second half.
- Myriad intends to invest over $35 million over the next few years to strengthen commercial capabilities, particularly in cancer care, with these expenses already factored into the 2026 guidance.
Jan 15, 2026, 1:15 AM
Myriad Genetics Provides 2025 Preliminary Results and 2026 Guidance, Outlines Strategic Focus
MYGN
Guidance Update
Product Launch
New Projects/Investments
- Myriad Genetics reported preliminary Q4 2025 revenue between $207 million and $209 million and full-year 2025 revenue between $822 million and $824 million.
- For full-year 2026, the company projects revenue between $860 million and $880 million, gross margin of 68%-69%, and adjusted EBITDA between $37 million and $49 million.
- Myriad Genetics is undergoing a strategic shift, focusing on the cancer care continuum and expanding its product portfolio, including new AI-enabled tests and significant investment in Minimal Residual Disease (MRD).
- The company anticipates achieving high-single-digit to low-double-digit revenue growth over the next five years, starting in 2025, driven by new product launches and strategic partnerships.
Jan 15, 2026, 1:15 AM
Myriad Genetics Reports Preliminary 2025 Results and Issues 2026 Guidance
MYGN
Guidance Update
Product Launch
New Projects/Investments
- Myriad Genetics reported preliminary Q4 2025 revenue of $207-$209 million and FY 2025 revenue of $822-$824 million.
- The company provided 2026 financial guidance, projecting total revenue of $860-$880 million, an adjusted gross margin of 68%-69%, and adjusted EBITDA of $37-$49 million. The mid-point of 2026 revenue guidance reflects an approximate 6% increase over the preliminary 2025 revenue mid-point.
- Myriad is strategically focusing on the Cancer Care Continuum and plans to launch new products in H1 2026, including an AI-enhanced Prolaris test for prostate cancer and initiating clinical testing for Precise MRD for breast cancer.
- In 2025, the company served 55K+ healthcare providers and reported 1.5M+ patient tests.
- Myriad plans to invest over $35 million in its commercial organization to drive strategic growth.
Jan 15, 2026, 1:15 AM
Quarterly earnings call transcripts for MYRIAD GENETICS.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more